The invention relates to a method for the prediction or prognosis of the response of a human subject suffering from cancer to treatment with an antagonist of the NK1 receptor, that allows the subjects to be classified into responders and non-responders. The invention also relates to the kit or device comprising the necessary elements for carrying out said method, and to the use thereof. Said predictive method allows the optimization of the treatment with said antagonists, for example, in relation to doses of use or association with other antitumor agents.
